146 related articles for article (PubMed ID: 32488989)
1. Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors.
Patel C; Goel S; Patel MR; Rangachari L; Wilbur JD; Shou Y; Venkatakrishnan K; Lockhart AC
Clin Pharmacol Drug Dev; 2020 Oct; 9(7):876-888. PubMed ID: 32488989
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
Voss MH; Gordon MS; Mita M; Rini B; Makker V; Macarulla T; Smith DC; Cervantes A; Puzanov I; Pili R; Wang D; Jalal S; Pant S; Patel MR; Neuwirth RL; Enke A; Shou Y; Sedarati F; Faller DV; Burris HA
Br J Cancer; 2020 Nov; 123(11):1590-1598. PubMed ID: 32913286
[TBL] [Abstract][Full Text] [Related]
3. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
Swaisland H; Plummer R; So K; Garnett S; Bannister W; Fabre MA; Dota C; Fielding A
Cancer Chemother Pharmacol; 2016 Oct; 78(4):775-84. PubMed ID: 27553432
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors.
Smith DC; Powderly J; Lee JJ; Shepard DR; Wallin J; Chaudhary A; Chao GY; Ng WT; Mitchell MI; Grau G; Kurek R; LoRusso P
Cancer Chemother Pharmacol; 2016 Aug; 78(2):271-80. PubMed ID: 27312733
[TBL] [Abstract][Full Text] [Related]
5. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
[TBL] [Abstract][Full Text] [Related]
7. Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.
Diamond JR; Bastos BR; Hansen RJ; Gustafson DL; Eckhardt SG; Kwak EL; Pandya SS; Fletcher GC; Pitts TM; Kulikowski GN; Morrow M; Arnott J; Bray MR; Sidor C; Messersmith W; Shapiro GI
Clin Cancer Res; 2011 Feb; 17(4):849-60. PubMed ID: 21131552
[TBL] [Abstract][Full Text] [Related]
8. Concentration-QTc modeling of sitravatinib in patients with advanced solid malignancies.
Dickinson A; Liu Y; Uvarov A; Peyret T; Marier JF; Chin C; Tran JQ
Clin Transl Sci; 2024 May; 17(5):e13808. PubMed ID: 38700272
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.
Freise KJ; Dunbar M; Jones AK; Hoffman D; Enschede SL; Wong S; Salem AH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):847-53. PubMed ID: 27586967
[TBL] [Abstract][Full Text] [Related]
10. No QTc Prolongation With Zanubrutinib: Results of Concentration-QTc Analysis From a Thorough QT Study in Healthy Subjects.
Mu S; Darpo B; Tang Z; Novotny W; Tawashi M; Xue H; Willett M; Lin L; Sahasranaman S; Ou YC
Clin Transl Sci; 2020 Sep; 13(5):923-931. PubMed ID: 32144955
[TBL] [Abstract][Full Text] [Related]
11. Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors.
Zhou X; Richardson DL; Dowlati A; Goel S; Sahebjam S; Strauss J; Chawla S; Wang D; Mould DR; Samnotra V; Faller DV; Venkatakrishnan K; Gupta N
Clin Pharmacol Drug Dev; 2023 Mar; 12(3):257-266. PubMed ID: 36382849
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants.
Gong X; Darpo B; Xue H; Punwani N; He K; Barbour AM; Epstein N; Landman R; Chen X; Yeleswaram S
Clin Pharmacol Drug Dev; 2020 Aug; 9(6):677-688. PubMed ID: 31821750
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors.
Deeken JF; Shimkus B; Liem A; Hill D; Gurtler J; Berghorn E; Townes L; Lu H; Trifan O; Zhang S
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1473-83. PubMed ID: 23589315
[TBL] [Abstract][Full Text] [Related]
14. Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.
Någård M; Ah-See ML; Strauss J; Wise-Draper T; Safran HP; Nadeau L; Edenfield WJ; Lewis LD; Rekić D; Dota C; Ottesen LH; Li Y; Mugundu GM
Cancer Chemother Pharmacol; 2023 Aug; 92(2):141-150. PubMed ID: 37368100
[TBL] [Abstract][Full Text] [Related]
15. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
Matz J; Graff C; Vainio PJ; Kallio A; Højer AM; Struijk JJ; Kanters JK; Andersen MP; Toft E
Clin Drug Investig; 2011 Nov; 31(11):799-811. PubMed ID: 21967071
[TBL] [Abstract][Full Text] [Related]
16. A Phase 1 Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics.
Gall J; Choi T; Riddle V; Van Wart S; Gibbons JA; Seroogy J
Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1032-1041. PubMed ID: 30650259
[TBL] [Abstract][Full Text] [Related]
17. A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.
Shimizu T; Kuboki Y; Lin CC; Yonemori K; Yanai T; Faller DV; Dobler L; Gupta N; Sedarati F; Kim KP
Target Oncol; 2022 Jan; 17(1):15-24. PubMed ID: 34843044
[TBL] [Abstract][Full Text] [Related]
18. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure-QTc in patients with advanced or refractory solid tumors.
Valade E; Dosne AG; Xie H; Kleiman R; Li LY; Perez-Ruixo JJ; Ouellet D
Cancer Chemother Pharmacol; 2019 Sep; 84(3):621-633. PubMed ID: 31280362
[TBL] [Abstract][Full Text] [Related]
20. Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies.
Mendzelevski B; Ferber G; Janku F; Li BT; Sullivan RJ; Welsch D; Chi W; Jackson J; Weng O; Sager PT
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1129-1141. PubMed ID: 29603015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
